SUNDAY, AUGUST 5, 2018

9:30 AM WELCOME AND INTRODUCTION:
Faina Shtern, MD, President and CEO, AdMeTech Foundation

9:45 AM SESSION II. DISEASE PROGRESSION AND CLINICAL OUTCOMES OF ADVANCED PROSTATE CANCER

Moderators:
Gerald L. Andriole, MD, Robert Royce Distinguished Professor, Chief of Urologic Surgery, and Vice-Chair, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, Siteman Cancer Center

Richard Babayan, MD, Professor and Chairman, Department of Urology, Boston University School of Medicine; and Chief of Urology, Boston Medical Center

Michael Blute, MD, Walter S. Kerr, Jr. Professor of Urology and Surgery, Harvard Medical School; and Chief of Urology, Massachusetts General Hospital

9:45 am State of the Art in “Smart” Prostate Cancer Screening: Defining the Need for Precision Diagnostics
Sigrid Carlsson, MD, PHD, MPH, Assistant Attending Epidemiologist, Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center and Associate Professor of Experimental Urology, Sahlgrenska Academy, Gothenburg University, Sweden

10:00 am Q & A

10:05 am IsoPSA, a Novel Structure-Based Assay for Screening
Eric Klein, MD, Chairman, Glickman Urological and Kidney Institute, Cleveland Clinic

10:20 am Q & A

10:25 am Current and Emerging Fluid-Based Molecular Diagnostics for Improving Risk Assessment and Selection of Patients for Biopsy

David Crawford, MD, E. David Crawford Distinguished Endowed Chair in Urology, University of Colorado, Denver

10:50 am Q & A

10:55 am Liquid Biopsy: Definition and Clinical Utility
Michael Donovan, MD, PhD, Professor of Pathology, Mount Sinai Medical Center

11:15 am Q & A
9:35 AM  Current and Emerging Imaging Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling

9:35 am  Multi-Parametric (mp) Magnetic Resonance Imaging and PI-RADS for Risk Assessment Prior to Biopsy

Jeffrey Weinreb, MD, Professor and Vice Chair for Strategic Planning and Innovation, Department of Diagnostic Radiology and Biomedical Imaging, Yale School of Medicine

9:50 am  mpMRI, PI-RADS and Multi-Modality Image Fusion for Target Definition and Tissue Sampling

Jelle Barentsz, MD, PhD, Chair and Professor of Radiology Prostate MR Center of Excellence, Nijmegen Medical Center, Radboud University, The Netherlands

10:05  Q & A

10:10 am  Coffee Break

10:30 am  Real-time High Resolution Micro-Ultrasound for Targeted Biopsies - A Multi-Center Comparison to mpMRI: Sangeet Ghai, MD, Associate Professor, Department of Medical Imaging, University of Toronto, Canada

10:45 am  Q & A

10:50 am  Effectiveness and Economic Implications of Population-Level Adoption of MRI-Guided Prostate Biopsies: Christopher Filson, MD, Assistant Professor of Urology, Emory University

11:05 am  Guidelines of the National Comprehensive Cancer Network (NCCN) for Early Detection of Prostate Cancer: Preston Sprenkle, MD, Assistant Professor of Surgery, Yale University School of Medicine; and Member, NCCN Prostate Cancer Early Detection Panel

11:20 am  Q & A

11:25 am  Integration of In Vitro Diagnostics with In Vivo Imaging: Sanoj Punnen, MD, Assistant Professor of Surgery, University of Miami Miller School of Medicine

11:40 am  Panel: Emerging Best Practices in Precision Screening and Diagnostic Assessment for Early Detection of Prostate Cancer. Moderators, Speakers and –

• Matthew Cooperberg, MD, MPH, Associate Professor, Department of Urology and Epidemiology Biostatistics, Helen Diller Family Chair in Urology, University of California, San Francisco

• Kelvin Moses, MD, PhD, Assistant Professor of Urology, Department of Urologic Surgery, Vanderbilt University Medical Center, Chief of Urology, Nashville General Hospital, and Member, Vanderbilt-Ingram Cancer Center

• Peter Pinto, MD, Head of Prostate Cancer Section, Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health

• Stephen Zappala, MD, Assistant Clinical Professor of Urology, Tufts University School of Medicine

12:30 pm  Lunch Break
01:30 PM  SESSION II. DIAGNOSTIC ASSESSMENT OF MEN WITH PROVEN LOCALIZED PROSTATE CANCER: Prediction of Progression, Staging, Patient Selection for Treatment and Post-Operative Assessment

Moderators:

David Crawford, MD
Angelo DeMarzo, MD, PhD, Associate Professor of Pathology, Urology, Oncology, Johns Hopkins University School of Medicine
Eric Klein, MD, Chairman, Glickman Urological and Kidney Institute, Cleveland Clinic

1:35 pm  **In Vivo Imaging**

1:35 pm  *Current Status of mpMRI and Multi-Modality Diagnostics – and Clinical Trial of the Eastern Cooperative Oncology Group and American College of Radiology Imaging Network:* Clare Tempany, MD, Ferenc Jolesz, MD Professor of Radiology, Harvard Medical School; Vice Chair, Research Radiology, Brigham and Women’s Hospital; and Director, National Center for Image-Guided Therapy

1:50 pm  **Q & A**

1:55 pm  *Radiomics and Machine Learning with Multiparametric Imaging:*
Masoom Haider, MD, Professor of Radiology and Vice Chair, Radiomics and Quantitative Imaging, University of Toronto, Canada

2:10 pm  **Q & A**

2:15 pm  *Radiogenomics of Tumor Habitats - Deciphering Prostate Cancer Heterogeneity:*
Radka Stoyanova, PhD, Professor and Director, Imaging and Biomarkers Research, Department of Radiation Oncology and Associate Member, Sylvester Comprehensive Cancer Center, Miller School of Medicine University of Miami

2:30 pm  **Q & A**

2:35 pm  **Tissue-Based Pathologic Assessment, Genomics and Phenotypic Biomarkers**

2:35 pm  *Anatomic Pathology:* Thomas Wheeler, MD, Chairman and Professor of Pathology, Baylor College of Medicine

2:50 pm  *Molecular Pathology:* Angelo DeMarzo, MD, PhD, Associate Professor of Pathology, Urology, Oncology, Johns Hopkins University School of Medicine

3:05 pm  **Q & A**

3:10 pm  *Genetic Cancer Profiling:* Eric Klein, MD, Chairman, Glickman Urological and Kidney Institute, Cleveland Clinic

3:25 pm  **Q & A**

3:30 pm  *Phenotypic Biomarkers and Precision Oncology:* David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York; and Medical Director for Associated Medical Professionals

3:45 pm  *Surrogate Outcomes*
Jennifer Rider, ScD, MPH, Assistant Professor, Department of Epidemiology, Boston University School of Public Health

4:00 pm  **Q & A**

4:05 pm  **Coffee Break**
Emerging Trends in Prostate Cancer Care: Impact of Precision Diagnostics
Matthew Cooperberg, MD, MPH

Q & A

Radiogenomics: Emerging and Future Impact on Treatment Selection and Monitoring

Active Surveillance - Sanoj Punnen, MD
Focal Treatment - Peter Pinto, MD
Immediate Standard Whole Gland Treatment: Radical Prostatectomy and EBRT – Adam Feldman, MD, MPH, Assistant Professor of Surgery and Director of Combined Harvard Urology Oncology Fellowship, Massachusetts General Hospital, Harvard Medical School

Q & A

Panel on Diagnostic Evaluation of Men with Proven Localized Prostate Cancer and its Impact on Treatment Selection and Monitoring

Speakers, Moderators and Panel Members -
- Comments on Ultrasound and Multi-Modality Imaging - Sangeet Ghai, MD
- Comments on Improved Diagnosis of Clinically Significant PC - Susan Noworolski, PhD, Professor, Department of Radiology, UCSF
- Comments on mpMRI for Cost-Effective Active Surveillance - Sejal Patel, MSc, Radboud University, The Netherlands
- Comments on Molecular Imaging - Heather Jacene, MD, Assistant Professor of Radiology and Associate Program Director, Brigham and Women's Joint Program in Nuclear Medicine, Harvard Medical School
- Comments on Non-Invasive PSMA - Daniel Margolis, MD, Associate Professor of Radiology and Director, Prostate MRI and Abdominal Imaging, Weill Cornell Medicine
- Comments on Intraoperative Molecular Imaging for Staging - Wolfgang Weber, MD, Professor and Chair, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany
- Comments on Multi-Modality Novel Nomograms for Improved Risk Stratification - Amita Shukla-Dave, PhD, Deputy Service Chief for Predictive Informatics, Memorial Sloan Kettering Cancer Center

Dinner Reception

Industry Leadership Session on Accelerating Innovation and Adoption - Role of Technology Assessment, Clinical Guidelines and Reimbursement Policy

Moderators:
Richard Frank, MD, PhD, Chief Medical Officer, Siemens Healthineers and Participant, US Vice President Joseph Biden’s Cancer Moonshot Program
Grannum Sant, MD, FRCS, FACS, Professor and Former Chair of Urology, Tufts University School of Medicine; Former Head, Oncology/Urology Medical Affairs, Sanofi, and Rare Genetic Diseases, Genzyme

Introduction: Four Hurdles to Adoption of Innovations into Clinical Practice - Richard Frank, MD, PhD

mpMRI: Clinical Utilization and Health Economics - Heinrich von Busch, PhD, Product Owner, Artificial Intelligence for Oncology Imaging; and Artem Boltyenkov, PhD, Senior Manager, Global Health Economics and Outcomes Research, Siemens Healthineers

PET/CT with Axumin (18F-fluciclovine): Clinical Implementation – Jonathan Allis, PhD, CEO, Blue Earth Diagnostics
8:10 pm  PET PSMA: Emerging Broad-Based Clinical Utility – Steven Rowe, MD, PhD, Assistant Professor of Radiology, Johns Hopkins University School of Medicine

8:15 PM  Improving Prostate Biopsy Guidance: Moving to 29 MHz Micro-Ultrasound – Brian Wodlinger, PhD, Manager, Advanced Development and Clinical Research, Exact Imaging

8:20 pm  In Vitro Diagnostics: Clinical Adoption - Kelvin Moses, MD, PhD

8:30 pm  Genomic Cancer Profiling: Clinical Role and State of Adoption

8:30 pm  Perspective from Myriad Genetics:
Brian Liu, PhD, Medical Science Liaison-Urology

8:35 pm  Perspective from Genomic Health:
Lisa Kaminsky, RN, BSN, CNOR, Sr. Medical Science Liaison

8:40 pm  Targeted Biopsy and Focal Treatment: Emerging Clinical Role - Antoine Leroy, President, Koelis

8:45 pm  Panel Discussion: Recommendations for Actions to Accelerate Adoption
Moderators, Speakers and Peter Pinto, MD; and Jeffrey Weinreb, MD

8:55 pm  Summary of Actions - Moderators

9:00 pm  Poster Session

SUNDAY, AUGUST 5, 2018

8:00 AM  SESSION III: PRECISION DIAGNOSTICS AND EMERGING ROLE OF FOCAL TREATMENT

Moderators:
Peter Pinto, MD
Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine
Clare Tempany, MD, Ferenc Jolesz, MD Professor of Radiology, Harvard Medical School and Vice Chair Research, Radiology, Brigham and Women’s Hospital; and Director, National Center for Image-Guided Therapy

8:05 am  Multimodality Precision Diagnostics for Target Definition

8:05 am  MRI/Ultrasound Fusion: Srinivas Vourganti, MD

8:15 am  Multi-Modality Imaging: Sadhna Verma, MD

8:25 am  Radiogenomics: John Feller, MD, Founder, Desert Medical Imaging

8:35 am  Q & A

8:40 am  Overview of Patient Selection, Monitoring and Outcomes

8:40 am  Radiology Perspective: Jurgen Futterer, MD, PhD, Interventional Radiologist, Nijmegen Medical Center and Professor, University of Twente, The Netherlands

8:55 am  Urology Perspective: Clinical Trial Design and Gold Nanoparticle-Directed Focal Ablation
Art Rastinehad, DO, FACOS, Associate Professor of Urology and Radiology, and Director, Focal Therapy and Interventional Urology Program, Icahn School of Medicine at Mount Sinai Health System
9:10 am  Panel Discussion: Moderators, Speakers

9:30 AM  SESSION IV: PRECISION ONCOLOGY FOR RECURRENT AND ADVANCED PROSTATE CANCER

Angelo DeMarzo, MD, PhD

Daniel Petrylak, MD, Professor of Medicine (Medical Oncology) and Urology; and Co-Director, Signal Transduction Research Program, Yale University Cancer Center

9:35 am  Overview of Advanced Prostate Cancer, including Oligometastatic Disease: Daniel Petrylak, MD

9:50 am  Q & A

9:55 am  Liquid Biopsy: David Nanus, MD, Mark W. Pasmantier Professor and Chief, Hematology and Oncology, New York-Presbyterian, and Director of Genitourinary Oncology, Weill Cornell Medicine

10:10 am  Q & A

10:15 am  Genomic Testing, including Germline Mutations: Angelo DeMarzo, MD, PhD

10:30 am  Q & A

10:35 am  Coffee Break

10:55 am  Molecular and Multi-Modality Imaging

11:10 am  LOCATE Trial - Impact of PET with 18F-fluciclovine on Management of Patients with Suspected Recurrence: Gerald L. Andriole, MD

11:25 am  Q & A

11:30 am  PSMA PET Review: Steven Rowe, MD, PhD

11:45 am  PSMA Based Theranostics of Prostate Cancer: Wolfgang Weber, MD

12:00 pm  Q & A

12:05 pm  Panel Discussion: Moderators, Speakers

12:30 pm – 1:30 pm  Lunch

1:30 pm  SESSION V. SUMMARY PANEL DISCUSSION

Moderators, Speakers, Panelists

Session Leaders: Gerald Andriole, MD, Matthew Cooperberg, MD, MPH, David Crawford, MD, Angelo Demarzo, MD, PhD, Masoom Heider, MD, Eric Klein, MD, Daniel Petrylak, MD, Peter Pinto, MD, Faina Shtern, MD, Clare Tempany, MD, and Wolfgang Weber, MD

1:30 pm  SESSION V-1. SUMMIT HIGHLIGHTS: Most Promising Current Clinical and Research Trends in Precision Screening, Diagnosis and Treatment and Expediting their Transfer from Laboratories to Patients

2:30 pm  Coffee Break

3:00 pm - 5:30 pm  SESSION V-2. BRAIN TRUST MEETING: Development of the Consensus Recommendations – Defining and Addressing Priority Needs in Precision Clinical Care by Designing Research, Medical Education and Training Programs